SB-284851-BT

Modify Date: 2024-04-08 18:25:59

SB-284851-BT Structure
SB-284851-BT structure
Common Name SB-284851-BT
CAS Number 219769-23-0 Molecular Weight 443.52
Density N/A Boiling Point N/A
Molecular Formula C26H26FN5O Melting Point N/A
MSDS N/A Flash Point N/A

 Use of SB-284851-BT


SB-284851-BT is an inhibitor of BRD4/p38α/BRDT. SB-284851-BT inhibits BRD4-BD1 (IC50=1.7 µM), p38α (Kd=0.47 nM), BRDT (1) (IC50=18 µM) and BRD4 (1)(IC50=3.7 µM). SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET)[1][2].

 Names

Name SB-284851-BT

 SB-284851-BT Biological Activity

Description SB-284851-BT is an inhibitor of BRD4/p38α/BRDT. SB-284851-BT inhibits BRD4-BD1 (IC50=1.7 µM), p38α (Kd=0.47 nM), BRDT (1) (IC50=18 µM) and BRD4 (1)(IC50=3.7 µM). SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET)[1][2].
Related Catalog
Target

p38α:0.47 nM (Kd)

BRD4-BD1:1.7 μM (IC50)

BRDT (1):18 μM (IC50)

BRD4(1):3.7 μM (IC50)

References

[1]. Divakaran A, et al. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem. 2018 Oct 25;61(20):9316-9334.  

[2]. Jin W, et al. Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions. Drug Discov Today. 2022 Jan;27(1):246-256.  

 Chemical & Physical Properties

Molecular Formula C26H26FN5O
Molecular Weight 443.52
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.